Effectiveness · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Number of participants with any adverse events№ of participants: 102(2 RCTs) · idiopathic hypersomnia
Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
OR 1.68 [0.28, 9.94]
Studies not reported
Low
Daytime sleepiness (ESS): change from baseline. · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Sleepiness · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Mortality (at the end of · adults receiving EN via nasogastric or gastrostomy tube
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes mortality (at the end of compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
1 finding from 1 review
Pneumonia · adults receiving EN via nasogastric or gastrostomy tube
It is very uncertain whether higher threshold (500 mL per six hours or greater) changes pneumonia (until discontinued or up to 28 days) compared with lower threshold (less than 500 mL per six hours) at time of aspiration (very low certainty).
1 finding from 1 review
Length of hospital stay · adults receiving EN via nasogastric or gastrostomy tube
1 finding from 1 review
Impaired social interaction · children aged 5 to 11 years with ASD
1 finding from 1 review
Social communication impairment · children aged 5 to 11 years with ASD
1 finding from 1 review
Stereotyped patterns of behaviour and interests · children aged 5 to 11 years with ASD
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐core symptoms of ASD · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in non‐core symptoms of ASD compared with placebo (low certainty).
1 finding from 1 review
Tolerability · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in tolerability compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of joint bleeding episodes per year (AJBR) · children or adults with hemophilia A or B
1 finding from 1 review
Intervention not reported
Number of total bleeds per year (ABR) · children or adults with hemophilia A or B
1 finding from 1 review
Intervention not reported
Treatment‐related adverse events · children or adults with hemophilia A or B
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · children or adults with hemophilia A
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in AJBR compared with pegylated liposome FVIII formulation (low certainty).
1 finding from 1 review
ABR · children or adults with hemophilia A
Prophylaxis with standard therapeutic factor concentrate showed no clear difference in ABR compared with pegylated liposome FVIII formulation (low certainty).
1 finding from 1 review
Any reported adverse effects · children or adults with hemophilia A
1 finding from 1 review
Number of joint bleeding episodes or joint bleeding frequency · participants with haemophilia
Prophylaxis regimen showed no clear difference in number of joint bleeding episodes or joint bleeding frequency compared with on‐demand treatment (low certainty).
1 finding from 1 review